BioCryst Pharmaceuticals, Inc.

NasdaqGS:BCRX Stock Report

Market Cap: US$1.5b

BioCryst Pharmaceuticals Management

Management criteria checks 4/4

BioCryst Pharmaceuticals' CEO is Jon Stonehouse, appointed in Jan 2007, has a tenure of 17.83 years. total yearly compensation is $4.78M, comprised of 13.9% salary and 86.1% bonuses, including company stock and options. directly owns 0.43% of the company’s shares, worth $6.42M. The average tenure of the management team and the board of directors is 4.7 years and 5.3 years respectively.

Key information

Jon Stonehouse

Chief executive officer

US$4.8m

Total compensation

CEO salary percentage13.9%
CEO tenure17.8yrs
CEO ownership0.4%
Management average tenure4.7yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

BioCryst's Orladeyo Outperforms, But Competition Remains A Threat (Rating Upgrade)

Sep 29

Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results

Aug 08
Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results

Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects

Jul 21

BioCryst: Estimate-Beating Q1 But Risks Are Considerable

May 07

Insufficient Growth At BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hampers Share Price

Apr 29
Insufficient Growth At BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hampers Share Price

BioCryst's Revenue Gains Offset By Rising Expenses: A Closer Look

Feb 27

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Jan 09
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking After Shares Rocket 34%

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares Lagging The Industry But So Is The Business

Jun 08
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares Lagging The Industry But So Is The Business

BioCryst Pharmaceuticals: Working To Increase Market Presence Of Orladeyo

Oct 11

BioCryst Pharmaceuticals promotes Sheridan to development chief

Sep 14

BioCryst wins FDA’s Orphan Drug status for bone disorder therapy

Aug 31

BioCryst to supply 10K doses of influenza drug Rapivab to US for ~$7M

Aug 25

BioCryst Orladeyo gets approval in Saudi Arabia to prevent hereditary angioedema attacks

Aug 18

BioCryst Pharmaceuticals Q2 2022 Earnings Preview

Aug 03

BioCryst Pharmaceuticals: Waiting For Clarity

Jul 25

BioCryst: A Prudent Diversification

Jun 24

CEO Compensation Analysis

How has Jon Stonehouse's remuneration changed compared to BioCryst Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$124m

Jun 30 2024n/an/a

-US$146m

Mar 31 2024n/an/a

-US$209m

Dec 31 2023US$5mUS$666k

-US$227m

Sep 30 2023n/an/a

-US$236m

Jun 30 2023n/an/a

-US$243m

Mar 31 2023n/an/a

-US$226m

Dec 31 2022US$7mUS$640k

-US$247m

Sep 30 2022n/an/a

-US$193m

Jun 30 2022n/an/a

-US$210m

Mar 31 2022n/an/a

-US$194m

Dec 31 2021US$7mUS$583k

-US$184m

Sep 30 2021n/an/a

-US$227m

Jun 30 2021n/an/a

-US$214m

Mar 31 2021n/an/a

-US$209m

Dec 31 2020US$6mUS$567k

-US$183m

Sep 30 2020n/an/a

-US$125m

Jun 30 2020n/an/a

-US$116m

Mar 31 2020n/an/a

-US$115m

Dec 31 2019US$2mUS$550k

-US$109m

Sep 30 2019n/an/a

-US$134m

Jun 30 2019n/an/a

-US$126m

Mar 31 2019n/an/a

-US$107m

Dec 31 2018US$4mUS$550k

-US$101m

Sep 30 2018n/an/a

-US$93m

Jun 30 2018n/an/a

-US$79m

Mar 31 2018n/an/a

-US$77m

Dec 31 2017US$4mUS$533k

-US$66m

Compensation vs Market: Jon's total compensation ($USD4.78M) is about average for companies of similar size in the US market ($USD5.54M).

Compensation vs Earnings: Jon's compensation has been consistent with company performance over the past year.

CEO

Jon Stonehouse (63 yo)

17.8yrs

Tenure

US$4,777,778

Compensation

Mr. Jon P. Stonehouse has been the Chief Executive Officer and Executive Director of BioCryst Pharmaceuticals, Inc. at Shionogi & Co. Ltd. since joining in January 8, 2007 and also has been its President s...

Leadership Team

NamePositionTenureCompensationOwnership
Jon Stonehouse
CEO, President & Executive Director17.8yrsUS$4.78m0.43%
$ 6.4m
Anthony Doyle
Senior VP4.6yrsUS$1.79m0.082%
$ 1.2m
Alane Barnes
Senior VP18.2yrsUS$1.93m0.089%
$ 1.3m
Helen Thackray
Chief Research & Development Officer3.7yrsUS$2.39m0.055%
$ 824.3k
Charles Gayer
Senior VP & Chief Commercial Officer4.8yrsUS$1.74m0.10%
$ 1.5m
John Bluth
Chief Communications Officerno datano datano data
Stephanie Angelini
Chief People Officerno datano datano data
William Sheridan
Chief Development Officer16.3yrsUS$2.66mno data
Yarlagadda Babu
Chief Discovery Officer11.1yrsUS$2.57mno data
Jinky Rosselli
Chief Data & Insights Officer3yrsno datano data
Philip George
Chief Strategy Officer2.2yrsno datano data
Clayton Fletcher
Chief Business Development Officer1.8yrsno datano data

4.7yrs

Average Tenure

57yo

Average Age

Experienced Management: BCRX's management team is considered experienced (4.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jon Stonehouse
CEO, President & Executive Director17.8yrsUS$4.78m0.43%
$ 6.4m
Vincent Milano
Independent Director3.3yrsUS$434.82k0.033%
$ 498.1k
Stephen Aselage
Independent Director5.8yrsUS$446.90k0.024%
$ 356.9k
Alan Levin
Independent Director4.8yrsUS$434.54k0.014%
$ 205.1k
George Abercrombie
Independent Director13.1yrsUS$432.74k0.0062%
$ 93.5k
Theresa Heggie
Independent Director5.9yrsUS$433.57k0.022%
$ 334.6k
Nancy Hutson
Independent Chair12.8yrsUS$470.30k0.034%
$ 509.4k
Steven K. Galson
Independent Director3.2yrsUS$424.40k0.017%
$ 253.0k
A. Sanders
Independent Director2.8yrsUS$423.15k0.010%
$ 152.1k
Amy McKee
Independent Director3.2yrsUS$422.32k0.010%
$ 152.7k

5.3yrs

Average Tenure

63.5yo

Average Age

Experienced Board: BCRX's board of directors are considered experienced (5.3 years average tenure).